Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Odense, Denmark.
Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Odense, Denmark ; Institute of Public Health, University of Copenhagen, Odense, Denmark.
Eur Thyroid J. 2014 Sep;3(3):173-8. doi: 10.1159/000365211. Epub 2014 Sep 2.
Graves' disease has been associated with an increased psychiatric morbidity. It is unclarified whether this relates to Graves' disease or chronic disease per se. The aim of our study was to estimate the prevalence of anxiety and depression symptoms in patients with Graves' disease compared to patients with another chronic thyroid disease, nodular goitre, and to investigate determinants of anxiety and depression in Graves' disease.
157 cross-sectionally sampled patients with Graves' disease, 17 newly diagnosed, 140 treated, and 251 controls with nodular goitre completed the Hospital Anxiety and Depression Scale (HADS). The differences in the mean HADS scores between the groups were analysed using multiple linear regression, controlling for socio-demographic variables. HADS scores were also analysed dichotomized: a score >10 indicating probable 'anxiety'/probable 'depression'. Determinants of anxiety and depression symptoms in Graves' disease were examined using multiple linear regression.
In Graves' disease levels of anxiety (p = 0.008) and depression (p = 0.014) were significantly higher than in controls. The prevalence of depression was 10% in Graves' disease versus 4% in nodular goitre (p = 0.038), anxiety was 18 versus 13% (p = 0.131). Symptoms of anxiety (p = 0.04) and depression (p = 0.01) increased with comorbidity. Anxiety symptoms increased with duration of Graves' disease (p = 0.04). Neither thyroid function nor autoantibody levels were associated with anxiety and depression symptoms.
Anxiety and depression symptoms were more severe in Graves' disease than in nodular goitre. Symptoms were positively correlated to comorbidity and duration of Graves' disease but neither to thyroid function nor thyroid autoimmunity.
Graves 病与精神疾病发病率增加有关。目前尚不清楚这是与 Graves 病有关，还是与慢性疾病本身有关。我们的研究目的是评估 Graves 病患者与另一种慢性甲状腺疾病结节性甲状腺肿患者相比，焦虑和抑郁症状的患病率，并探讨 Graves 病中焦虑和抑郁的决定因素。
157 名 Graves 病横断面样本患者，17 名新诊断患者，140 名治疗患者和 251 名结节性甲状腺肿对照组完成了医院焦虑抑郁量表（HADS）。使用多元线性回归，控制社会人口统计学变量，分析组间平均 HADS 评分的差异。还对 HADS 评分进行了二分分析：得分>10 表示可能存在“焦虑”/可能存在“抑郁”。使用多元线性回归检查 Graves 病中焦虑和抑郁症状的决定因素。
Graves 病中焦虑（p=0.008）和抑郁（p=0.014）水平明显高于对照组。Graves 病的抑郁患病率为 10%，结节性甲状腺肿为 4%（p=0.038），焦虑患病率为 18%比 13%（p=0.131）。焦虑（p=0.04）和抑郁（p=0.01）症状随合并症而增加。Graves 病的病程与焦虑症状的增加呈正相关（p=0.04）。甲状腺功能或自身抗体水平与焦虑和抑郁症状均无关联。
Graves 病中的焦虑和抑郁症状比结节性甲状腺肿更严重。症状与合并症和 Graves 病的病程呈正相关，但与甲状腺功能或甲状腺自身免疫无关。
